Incidence, Clearance and Persistence of Anal HPV in Men who Have Sex with Men Living with HIV: Implications for HPV Vaccination.
Men who have sex with men (MSM) living with HIV have a high risk of anal cancer. We estimate the likely benefit of HPV vaccination amongst participants of the Anal Cancer Examination (ACE) study. Anal swabs were collected for the detection and genotyping of anal HPV DNA by Linear Array (Roche Diagnostics) in this two-year multicentre prospective cohort. We calculated the proportion of men, stratified by age, without detectable vaccine-type-specific DNA. Overall, 255 men, with a median age of 50 years (IQR 44-56) contributed 488.9 person-years of follow-up. After two years of follow up, 149 (58%, 95% CI:52-65) had at least one high-risk HPV (HRHPV), and 71 (28%, 95% CI:22-34) had HPV types 16/18 detected. Assuming that DNA negative men would receive vaccine-protection, vaccination at baseline could potentially prevent HRHPV infection in 10.2% of men (95% CI:6.8-14.6, 26/255) two years later from incident HRHPV covered by the bivalent and quadrivalent vaccine, and 29.4% of men (95% CI:23.9-35.4, 75/255) from incident HRHPV covered by the nonavalent vaccine. Though there is high prevalence of anal HPV in MSM living with HIV, there was also a high incidence of HRHPV vaccine types in the two-year follow up indicating potential for prevention if these men were not previously infected with HPV vaccine types and were vaccinated at their baseline visit.